• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

道德层面令人不安的全球药物差距。

The morally uncomfortable global drug gap.

作者信息

Cohen-Kohler J C

机构信息

Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.

出版信息

Clin Pharmacol Ther. 2007 Nov;82(5):610-4. doi: 10.1038/sj.clpt.6100359. Epub 2007 Sep 26.

DOI:10.1038/sj.clpt.6100359
PMID:17898710
Abstract

Pharmaceuticals are one of the cornerstones of human development as their rational consumption can reduce morbidity and mortality rates and enhance the quality of life. Pharmaceuticals have curative and therapeutic qualities, so they cannot be considered as ordinary products. In line with this, ensuring public policy fosters access to medicines demands thoughtful and careful consideration, as it is often about whether a patient lives or dies. Despite the flow of international aid for pharmaceuticals, particularly used for the treatment of HIV/AIDS, tuberculosis, and malaria, there is a morally concerning drug gap globally; the World Health Organization (WHO) notes that one-third of the global population lacks regular access to essential medicines and that in some parts of Asia and Africa these figures are even more severe.(1) But what is troubling is that, despite the knowledge that we live in a world with inequitable access to medicines, we have not examined how we need to put in place policies that not only support drug access but also do not undermine it, which will be addressed later. What is promising, is that slowly, a paradigm shift is taking place. Access to essential medicines is increasingly viewed as a fundamental human right, with international human rights laws placing attendant obligations on states to ensure access.(2, 3) But governments also have to ensure that the policy environment is supportive of access to medicines. And this includes making sure that social policy is not undercut by economic interests.

摘要

药品是人类发展的基石之一,因为合理使用药品可以降低发病率和死亡率,提高生活质量。药品具有治疗功效,因此不能被视为普通产品。与此相符的是,确保公共政策促进药品可及性需要深思熟虑和谨慎考量,因为这往往关乎患者的生死。尽管有国际药品援助,特别是用于治疗艾滋病毒/艾滋病、结核病和疟疾的援助,但全球仍存在令人担忧的药品缺口;世界卫生组织(WHO)指出,全球三分之一的人口无法定期获得基本药物,在亚洲和非洲的一些地区,这些数字更为严峻。(1) 但令人不安的是,尽管我们知道生活在一个药品可及性不平等的世界里,但我们尚未审视如何制定不仅支持药品可及性而且不会破坏它的政策,这将在后面讨论。有希望的是,一种范式转变正在慢慢发生。获得基本药物越来越被视为一项基本人权,国际人权法规定各国负有确保可及性的相应义务。(2, 3) 但政府还必须确保政策环境有利于药品可及性。这包括确保社会政策不会被经济利益削弱。

相似文献

1
The morally uncomfortable global drug gap.道德层面令人不安的全球药物差距。
Clin Pharmacol Ther. 2007 Nov;82(5):610-4. doi: 10.1038/sj.clpt.6100359. Epub 2007 Sep 26.
2
Access to essential medicines: a Hobbesian social contract approach.基本药物的可及性:一种霍布斯式社会契约方法
Dev World Bioeth. 2005 May;5(2):121-41. doi: 10.1111/j.1471-8847.2005.00108.x.
3
TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.《与贸易有关的知识产权协定》、药品专利与基本药物的获取:从西雅图到多哈的漫长之路
Chic J Int Law. 2002 Spring;3(1):27-46.
4
Gender and medicines: an international public health perspective.性别与药物:国际公共卫生视角
J Womens Health (Larchmt). 2005 Jan-Feb;14(1):82-6. doi: 10.1089/jwh.2005.14.82.
5
Essential medicines for the whole world.全球的基本药物。
Clin Pharmacol Ther. 2007 Nov;82(5):500-3. doi: 10.1038/sj.clpt.6100388.
6
Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?《与贸易有关的知识产权协定》(TRIPS协定)在拉丁美洲和加勒比地区的实施是否产生了有利于公共卫生的知识产权立法?
Bull World Health Organ. 2004 Nov;82(11):815-21. Epub 2004 Dec 14.
7
Addressing legal and political barriers to global pharmaceutical access: options for remedying the impact of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the imposition of TRIPS-plus standards.消除全球药品获取的法律和政治障碍:补救《与贸易有关的知识产权协定》(TRIPS协定)的影响及实施TRIPS-plus标准的应对选项。
Health Econ Policy Law. 2008 Jul;3(Pt 3):229-56. doi: 10.1017/S1744133108004477.
8
Ensuring access to essential medicines: some economic considerations.确保基本药物的可及性:一些经济考量
Spec Law Dig Health Care Law. 2003 Jul(291):9-25.
9
GATT and the gap: how to save lives.
AIDS Treat News. 1998 Nov 20(No 307):1, 3-6.
10
Health GAP coalition--new group for international treatment access.
AIDS Treat News. 1999 Mar 19(No 315):5-6.

引用本文的文献

1
Histological, Biochemical, and Hematological Effects of Goniothalamin on Selective Internal Organs of Male Rats.角鲨胺对雄性大鼠特定内脏器官的组织学、生化及血液学影响
J Toxicol. 2019 Apr 23;2019:6493286. doi: 10.1155/2019/6493286. eCollection 2019.
2
Medication misuse among elderly population in Pakistan.巴基斯坦老年人群中的药物滥用问题。
Ther Adv Drug Saf. 2016 Jun;7(3):122-3. doi: 10.1177/2042098616637250. Epub 2016 Mar 2.
3
Beyond access to medicines: Eliciting high-income country support for a new global health research and development paradigm.
超越药品获取:争取高收入国家对新的全球卫生研究与发展范式的支持。
J Glob Health. 2013 Dec;3(2):020303. doi: 10.7189/jogh.03.020303.
4
Exploring knowledge and perceptions of generic medicines among drug retailers and community pharmacists.探索药品零售商和社区药剂师对非专利药品的了解及认知。
Indian J Pharm Sci. 2012 Nov;74(6):571-5. doi: 10.4103/0250-474X.110611.
5
Access to medicines from a health system perspective.从卫生系统角度看药品的可及性。
Health Policy Plan. 2013 Oct;28(7):692-704. doi: 10.1093/heapol/czs108. Epub 2012 Nov 22.
6
Pharmacogenomic technologies: a necessary "luxury" for better global public health?药物基因组学技术:改善全球公共卫生的必要“奢侈品”?
Global Health. 2011 Aug 24;7:30. doi: 10.1186/1744-8603-7-30.
7
A systematic review of pharmacokinetics studies in children with protein-energy malnutrition.蛋白质-能量营养不良儿童的药代动力学研究系统评价。
Eur J Clin Pharmacol. 2010 Oct;66(10):1025-35. doi: 10.1007/s00228-010-0851-0. Epub 2010 Jun 16.
8
Which new approaches to tackling neglected tropical diseases show promise?哪些新方法有望解决被忽视的热带病?
PLoS Med. 2010 May 18;7(5):e1000255. doi: 10.1371/journal.pmed.1000255.
9
Published pediatric randomized drug trials in developing countries, 1996-2002.1996-2002 年发展中国家发表的儿科随机药物试验。
Paediatr Drugs. 2010 Apr 1;12(2):99-103. doi: 10.2165/11316260-000000000-00000.